Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Others

Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments R&D In Process Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Ratios

Immunovant (IMVT) Long-Term Debt Repayments (2019 - 2020)

Immunovant filings provide 2 years of Long-Term Debt Repayments readings, the most recent being $134000.0 for Q4 2020.

Quarterly Long-Term Debt Repayments changed N/A to $134000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $134000.0 through Sep 2021, down 95.62% year-over-year, with the annual reading at $3.2 million for FY2021, 27.6% up from the prior year.
Long-Term Debt Repayments hit $134000.0 in Q4 2020 for Immunovant, down from $202000.0 in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $2.9 million in Q2 2020 and bottomed at $134000.0 in Q4 2020.